How ‘diabesity drugs’ could change the investment landscape

from In the market for more · host IG Group

Trial results from Eli Lilly add to a growing body of evidence that suggests GLP-1 drugs, which include treatments like Lilly’s Mounjaro and Novo Nordisk’s Wegovy have medical benefits beyond diabetes and weight loss. Tematica CIO Chris Versace explains how these so-called ‘diabesity drugs‘ could affect healthcare and why their impact, positive and negative, could not be known for some time. He also discusses the impact of oil prices on monetary policy and Netflix.Any opinion, news, research, analysis, or other information does not constitute investment or trading advice. Follow us on Twitter, Instagram, and YouTube *Your capital is at risk. 71% of retail CFD accounts lose money*

Episode metadata supplied by the publisher feed · Published Apr 24, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

How ‘diabesity drugs’ could change the investment landscape

0:00 9:27

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of In the market for more?

This episode is 9 minutes long.

When was this In the market for more episode published?

This episode was published on April 24, 2024.

Can I download this In the market for more episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!